Mercury Laboratories Ltd (MERCURYLAB) is currently trading at 792.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Mercury Laboratories Limited, established in 1962, is a pharmaceutical company specializing in medicinal drugs and formulations. Incorporated as a private limited company in 1982, it later transitioned to a publicly listed entity in 1992. The company consistently generates profits and pays dividends, indicating robust financial health and shareholder value. Mercury Laboratories has a long-standing presence in the pharmaceutical industry, highlighting its stability and experience. The company's transformation from a partnership firm to a public limited company showcases strategic business development over the decades.

Over the past 52 weeks, Mercury Laboratories Ltd has traded between a low of ₹776.00 and a high of ₹976.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Mercury Laboratories Ltd has a market capitalization of approximately 95.08. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Mercury Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.22 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 95.08 Cr, Mercury Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Mercury Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Mercury Laboratories Ltd is 19.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.